New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05233436
First seen Feb 21, 2026 · Last updated Jun 12, 2026 · Updated 21 times
Summary
This early-phase study tested an experimental drug (PF-07265028) alone or with another drug (sasanlimab) in 21 people with advanced solid tumors like lung, stomach, or bladder cancer. The goal was to find the safest dose and see if the drugs shrink tumors. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
HonorHealth Scottsdale Shea Medical Center
Scottsdale, Arizona, 85260, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The Cancer Institute Hospital of JFCR
Koto, Tokyo, 135-8550, Japan
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.